

Amphastar Pharmaceuticals, Inc.
Form 3
June 24, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | |
|---|---|--|--|---|---|
| <p>1. Name and Address of Reporting Person *</p> <p>Â Gerst Diane G.</p> <p>(Last) (First) (Middle)</p> <p>C/O AMPHASTAR PHARMACEUTICALS, INC.,Â 11570 6TH STREET</p> <p>(Street)</p> <p>RANCHO CUCAMONGA,Â CAÂ 91730</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>06/24/2014</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Amphastar Pharmaceuticals, Inc. [AMPH]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Corp. Sr. VP of Quality Assur.</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> | <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p> |
|---|---|--|--|---|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock | 4,728 | D | Â |
| Common Stock | 8,080 ⁽¹⁾ | D | Â |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security | 4. Conversion or Exercise | 5. Ownership Form of | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|---------------------------|----------------------|--|
|---|---|--|---------------------------|----------------------|--|

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 3

| | Date Exercisable | Expiration Date | (Instr. 4) Title | Amount or Number of Shares | Price of Derivative Security | Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | |
|-----------------------------|------------------|-----------------|---------------------|----------------------------|------------------------------|--|---|
| Stock Option (Right to Buy) | Â <u>(2)</u> | 07/28/2014 | Common Stock | 10,000 | \$ 14.8 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 05/15/2015 | Common Stock | 9,782 | \$ 14.8 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 05/15/2015 | Common Stock | 218 | \$ 14.8 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 12/21/2016 | Common Stock | 4,000 | \$ 30.57 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 12/21/2016 | Common Stock | 1,000 | \$ 30.57 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 12/30/2017 | Common Stock | 8,767 | \$ 31.65 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 12/30/2017 | Common Stock | 5,233 | \$ 31.65 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 08/28/2018 | Common Stock | 2,522 | \$ 35.32 | D | Â |
| Stock Option (Right to Buy) | Â <u>(2)</u> | 08/28/2018 | Common Stock | 8,478 | \$ 35.32 | D | Â |
| Stock Option (Right to Buy) | Â <u>(3)</u> | 08/05/2019 | Common Stock | 3,500 | \$ 20.26 | D | Â |
| Stock Option (Right to Buy) | Â <u>(4)</u> | 08/05/2019 | Common Stock | 8,500 | \$ 20.26 | D | Â |
| Stock Option (Right to Buy) | Â <u>(5)</u> | 03/08/2021 | Common Stock | 9,000 | \$ 11.41 | D | Â |
| Stock Option (Right to Buy) | Â <u>(6)</u> | 03/08/2021 | Common Stock | 6,000 | \$ 11.41 | D | Â |
| Stock Option (Right to Buy) | Â <u>(7)</u> | 12/22/2021 | Common Stock | 4,954 | \$ 14.23 | D | Â |
| Stock Option (Right to Buy) | Â <u>(8)</u> | 12/22/2021 | Common Stock | 10,046 | \$ 14.23 | D | Â |
| Stock Option (Right to Buy) | Â <u>(9)</u> | 11/07/2022 | Common Stock | 6,183 | \$ 10.48 | D | Â |
| Stock Option (Right to Buy) | Â <u>(10)</u> | 11/07/2022 | Common Stock | 13,817 | \$ 10.48 | D | Â |
| Stock Option (Right to Buy) | Â <u>(11)</u> | 07/30/2023 | Common Stock | 8,223 | \$ 10.93 | D | Â |

| | | | | | | | |
|-----------------------------|--------|------------|--------------|--------|----------|---|---|
| Stock Option (Right to Buy) | Â (12) | 07/30/2023 | Common Stock | 19,777 | \$ 10.93 | D | Â |
| Stock Option (Right to Buy) | Â (13) | 04/14/2024 | Common Stock | 11,775 | \$ 14.4 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|----------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Gerst Diane G. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730 | Â | Â | Â Corp. Sr. VP of Quality Assur. | Â |

Signatures

/s/Diane G. Gerst, by Power of Attorney 06/24/2014

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This represents deferred stock units that were granted on 4/14/2014 and vest over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (2) This option is fully vested and exercisable.
 - (3) This option was granted on 8/5/2009 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (4) This option was granted on 8/5/2009 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (5) This option was granted on 3/8/2011 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (6) This option was granted on 3/8/2011 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (7) This option was granted on 12/22/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (8) This option was granted on 12/22/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (9) This option was granted on 11/7/2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
 - (10)

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 3

This option was granted on 11/7/2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.

- (11) This option was granted on 7/30/2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.

- (12) This option was granted on 7/30/2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.

- (13) This option was granted on 4/14/2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.